Skip to main content

Advertisement

SpringerLink
Log in

Rate of Curative Surgery in Real-world Patients with Unresectable Metastatic Colorectal Cancer Treated with FOLFOXIRI ± Bevacizumab: A Western Canadian Province Experience

  • Original Research
  • Published:
Journal of Gastrointestinal Cancer Aims and scope Submit manuscript

Abstract

Background

Recent evidence from randomized trials suggests that FOLFOXIRI (fluorouracil, oxaliplatin, and irinotecan) ± bevacizumab is associated with higher response rates, with the potential for conversion of unresectable to resectable disease in metastatic colorectal cancer (mCRC). However, limited evidence is available on the efficacy and safety of this regimen in real-world patients with mCRC. The current study aims to evaluate the conversion rate and safety of FOLFOXIRI ± bevacizumab in real-world patients with unresectable mCRC.

Methods

In this retrospective multicenter population–based cohort study, patients who were diagnosed with unresectable mCRC between January 2015 and December 2018 in Saskatchewan and received FOLFOXIRI ± bevacizumab were assessed. Kaplan–Meier survival methods and the log-rank test were performed.

Results

A total of 28 eligible patients with a median age of 51 years (interquartile range 39–60) and a male:female ratio of 11:17 were identified; 39% had rectal cancer, 46% had extrahepatic disease, and 46% had bilobar liver metastases. Overall, 63% of the patients had a positive response to FOLFOXIRI ± bevacizumab and 53% underwent metastasectomy. Of all patients 60% had grade 3/4 toxicity and 32% required hospital admission. No treatment-related mortality was noted. After 4 years, 50% of the patients were alive. Median progression-free survival of patients who underwent surgery was 18 months (95% CI 11.3–24.7) versus 11 months (4–18.1) without surgery (p = 0.28). Median overall survival of patients with surgery was 33 months (17.5–48.5) versus 16 months (8.3–23.7) without surgery (p = 0.03).

Conclusion

The current study suggests that FOLFOXIRI ± bevacizumab therapy in real-world patients with mCRC is associated with a high rate of conversion from unresectable to resectable metastatic disease. Patients with metastasectomy had better survival.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Arnold M, Sierra MS, Laversanne M, et al. Global patterns and trends in colorectal cancer incidence and mortality. Gut. 2017;66(4):683–91.

    Article  Google Scholar 

  2. Bartlettt DL, Chu E. Can metastatic colorectal cancer be cured? Oncology. 2012;26:266–75.

    Google Scholar 

  3. Cummings LC, Payes JD, Cooper GS. Survival after hepatic resection in metastatic colorectal cancer: a population-based study. Cancer. 2007;109:718.

    Article  Google Scholar 

  4. Morris EJ, Forman D, Thomas JD, et al. Surgical management and outcomes of colorectal cancer liver metastases. Br J Surg. 2010;97:1110.

    Article  CAS  Google Scholar 

  5. Rees M, Tekkis PP, Welsh FK, et al. Evaluation of long-term survival after hepatic resection for metastatic colorectal cancer: a multifactorial model of 929 patients. Ann Surg. 2008;247:125.

    Article  Google Scholar 

  6. Simmonds PC, Primrose JN, Colquitt JL, et al. Surgical resection of hepatic metastases from colorectal cancer: a systematic review of published studies. Br J Cancer. 2006;94:982.

    Article  CAS  Google Scholar 

  7. Wei AC, Greig PD, Grant D, et al. Survival after hepatic resection for colorectal metastases: a 10-year experience. Ann Surg Oncol. 2006;13:668–92.

    Article  Google Scholar 

  8. Fernandez FG, Drebin JA, Linehan DC, et al. Five-year survival after resection of hepatic metastases from colorectal cancer in patients screened by positron emission tomography with F-18 fluorodeoxyglucose (FDG-PET) Ann Surg. 2004;240:438–447.

  9. Lee WS, Yun SH, Chun HK, et al. Clinical outcomes of hepatic resection and radiofrequency ablation in patients with solitary colorectal liver metastasis. J Clin Gastroenterol. 2008;42(8):945–9.

    Article  Google Scholar 

  10. Lordan JT, Riga A, Worthington TR, Karanjia ND. Early and long-term outcomes of patients undergoing liver resection and diaphragm excision for advanced colorectal liver metastases. Ann R Coll Surg Engl. 2009;91(6):483–8.

    Article  Google Scholar 

  11. Nikfarjam M, Shereef S, Kimchi ET, et al. Survival outcomes of patients with colorectal liver metastases following hepatic resection or ablation in the era of effective chemotherapy. Ann Surg Oncol. 2009;16(7):1860–7.

    Article  Google Scholar 

  12. Choti MA, Sitzmann JV, Tiburi MF, et al. Trends in long-term survival following liver resection for hepatic colorectal metastases. Ann Surg. 2002;235(6):759–66.

    Article  Google Scholar 

  13. Ahmed S, Johnson K, Ahmed O, Iqbal N. Advances in the management of colorectal cancer: from biology to treatment. Int J Colorectal Dis. 2014;29:1031–42.

    Article  Google Scholar 

  14. Kanthan R, Senger JL, Ahmed S, Kanthan SC. Recent advances in the management of stage IV colon cancer. J Cancer Ther. 2012;3:1104–18.

    Article  Google Scholar 

  15. Loupakis F, Cremolini C, Masi G, et al. Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer. N Engl J Med. 2014;371:1609–18.

    Article  Google Scholar 

  16. Gruenberger T, Bridgewater J, Chau I, et al. Bevacizumab plus mFOLFOX-6 or FOLFOXIRI in patients with initially unresectable liver metastases from colorectal cancer: the OLIVIA multinational randomised phase II trial. Ann Oncol. 2015;26:702–8.

    Article  CAS  Google Scholar 

  17. Falcone A, Ricci S, Brunetti I, et al. Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest. J Clin Oncol. 2007;25:1670.

    Article  CAS  Google Scholar 

  18. Masi G, Vasile E, Loupakis F, et al. Randomized trial of two induction chemotherapy regimens in metastatic colorectal cancer: an updated analysis. J Natl Cancer Inst. 2011;103:21.

    Article  Google Scholar 

  19. Tomasello G, Petrelli F, Ghidini M, et al. FOLFOXIRI plus bevacizumab as conversion therapy for patients with initially unresectable metastatic colorectal cancer: a systematic review and pooled analysis. JAMA Oncol. 2017;3:e170278.

    Article  Google Scholar 

  20. Ahmed S, Leis A, Kanthan S, et al. Surgical management of the primary tumor in stage IV colorectal cancer: a confirmatory retrospective cohort study. J Cancer. 2016;7:837–45.

    Article  Google Scholar 

  21. Caputo F, Santini C, Bardasi C, et al. BRAF-mutated colorectal cancer: clinical and molecular insights. Int J Mol Sci. 2019;20(21):5369.

    Article  CAS  Google Scholar 

  22. Conversion From Unresectable To Resectable Metastatic Colorectal Cancer. (CONVERSION) https://clinicaltrials.gov/ct2/show/NCT03401294

  23. Ahmed S, Anderson D, Chalchal H, et al. Conversion from unresectable to resectable liver metastases in real-world patients with liver-only metastatic colorectal cancer (mCRC) treated with FOLFOXIRI plus bevacizumab: The Conversion trial. J Clin Onc 2021;39:3suppl.

Download references

Acknowledgements

We acknowledge Saskatchewan Cancer Agency and its Data Access Committee for providing support for this research.

Funding

This study was funded by the 2019 Dean’s Summer Student Research Project grant at University of Saskatchewan, College of Medicine.

Author information

Authors and Affiliations

  1. College of Medicine, University of Saskatchewan, Saskatoon, SK, Canada

    Tayyaba Bhatti

  2. Department of Surgery, University of Saskatchewan, Saskatoon, SK, Canada

    Michael Moser, John Shaw & Dilip Gill

  3. Univeristy of Toronto, Toronto, ON, Canada

    Kiat Tsong Tan

  4. Allan Blair Cancer Centre, Regina, SK, Canada

    Haji Chalchal & Osama Souied

  5. Saskatoon Cancer Centre, University of Saskatchewan, Saskatoon, Canada

    Duc Le, Adnan Zaidi & Shahid Ahmed

Authors
  1. Tayyaba Bhatti
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Michael Moser
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Kiat Tsong Tan
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Haji Chalchal
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Osama Souied
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Duc Le
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. John Shaw
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Adnan Zaidi
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Dilip Gill
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Shahid Ahmed
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Shahid Ahmed.

Ethics declarations

Ethics

This study was approved by the University of Saskatchewan’s Biomedical Research Ethic Board.

Conflict of Interest

The authors declare no competing interests.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Bhatti, T., Moser, M., Tan, K.T. et al. Rate of Curative Surgery in Real-world Patients with Unresectable Metastatic Colorectal Cancer Treated with FOLFOXIRI ± Bevacizumab: A Western Canadian Province Experience. J Gastrointest Canc 53, 427–433 (2022). https://doi.org/10.1007/s12029-021-00634-w

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12029-021-00634-w

Keywords

Search

Navigation